Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges

(2014) Siwen Hu-Lieskovan et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

(2013) S. Mok et al.   CANCER RESEARCH

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

(2013) Bastian Schilling et al.   INTERNATIONAL JOURNAL OF CANCER

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production

(2013) A. Michelucci et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunological consequences of selective BRAF inhibitors in malignant melanoma

(2013) Bastian Schilling et al.   OncoImmunology

Cellular Constituents of Immune Escape within the Tumor Microenvironment

(2012) S. P. Kerkar et al.   CANCER RESEARCH

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

(2012) Richard C. Koya et al.   CANCER RESEARCH

Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination

(2012) Ahmad A. Tarhini et al.   JOURNAL OF IMMUNOTHERAPY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis

(2011) Noa Novershtern et al.   CELL

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

A flexible R package for nonnegative matrix factorization

(2010) Renaud Gaujoux et al.   BMC BIOINFORMATICS

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility

(2010) G. Solinas et al.   JOURNAL OF IMMUNOLOGY

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032

(2010) Jonas N Søndergaard et al.   Journal of Translational Medicine

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures

(2010) Seema B. Plaisier et al.   NUCLEIC ACIDS RESEARCH

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses

(2010) R. C. Koya et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy

(2009) S. J. Priceman et al.   BLOOD